Moreover, the aberrant activation of IL-23/IL-17 axis in obese patients with colon adenocarcinoma is considered to contribute to a favorable TME for cancer progression through several pathways, such as local recruitment of MDSCs, increased expression of Bcl-2 and Bcl-x antiapoptotic molecules in cancer cells or local VEGF release (Table 1) [110,118]. The gene discussed is IL17A; the disease is cancer.